A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections

Kohei Hara, Shigeru Kohno, Hironobu Koga, Kazuo Takebe, Masashi Tamura, Kazuki Konishi, Akiho Ohara, Masafumi Masuda, Takashi Tsuruya, Kazuyasu Abe, Tamotsu Takishima, Yasuo Tanno, Akira Watanabe, Masakichi Motomiya, Shigeo Takizawa, Nobuki Aoki, Izumi Hayashi, Kaoru Shimada, Junzaburo Kabe, Kouichiro KudouKouichiro Nakata, Tatsuo Nakatani, Kohya Shiba, Hiroyuki Kobayashi, Shin Kawai, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Masanori Matsumura, Kou Murohashi, Kaneo Suzuki, Hiroshi Takahashi, Takashi Sakuma, Noboru Syouji, Atsuhiko Sato, Masatoshi Iwata, Kaoru Shimokata, Hiroshi Saito, Takanao Murate, Hidetaka Kawatsu, Toshihiko Takeuchi, Yoshimitsu Hayashi, Hidekazu Hanaki, Masahito Kato, Jyouichi Kato, Ikuji Usami, Fumiyuki Kuze, Ryoichi Amitani, Fumio Miki, Kazuya Higashino, Shinsuke Tamura, Yasuko Hyodo, Midori Mikami, Takahiro Tsutsui, Hitoshi Yoshida, Shigeki Shibamoto, Takashi Sonoda, Naoki Togawa, Rinzo Soejima, Tsuyoshi Ogura, Fumitaka Ogushi, Michio Yamakido, Kenji Hasegawa, Takao Sasaki, Yuji Sugimoto, Yoshiro Sawae, Nobuyuki Shimono, Atsushi Shinoda, Tsuneo Ishibashi, Masayoshi Takamoto, Akira Kajiki, Yoshiya Kitahara, Hozumi Yamada, Osamu Katoh, Keizo Matsumoto, Atsushi Takahashi, Masaru Nasu, Yoichiro Goto, Atsushi Saito, Mitsuyoshi Nakashima, Keizo Yamaguchi, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of chronic respiratory tract infection, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 81.3% in the PAPM/BP group and 81.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.0% in the PAPM/BP group and 87.3% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 76.7% in the PAPM/BP group and 74.4% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 2.5% in the PAPM/BP group and 5.1% in the IPM/CS group. Abnormal laboratory data were found in 28.8% and 29.0% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 80.0% in the PAPM/BP group and 78.9% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 81.3% in the PAPM/BP group and 84.5% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of chronic respiratory tract infection is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.

Original languageEnglish
Pages (from-to)613-637
Number of pages25
JournalChemotherapy
Volume40
Issue number5
DOIs
Publication statusPublished - 1992 May

Keywords

  • Chronic respiratory tract infection
  • Comparative study
  • IPM/CS
  • PAPM/BP
  • Panipenem/betamipron

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections'. Together they form a unique fingerprint.

Cite this